Moderna shares extended losses in Friday premarket trading, falling 3.36% to $137.98, after the biotechnology company priced an upsized $2.6 billion private offering of 0.00% convertible senior notes due 2032, expanded from a $2.0 billion target. Initial purchasers received an option to buy up to an additional $400 million of notes. The notes initially convert at about $210.58 per share, a 47.5% premium to the Aug. 27 close of $142.77, when the stock dropped 4.60% on the upsizing. Moderna expects net proceeds of about $2.56 billion, or roughly $2.96 billion if the option is fully exercised, and plans to use about $285 million for capped call transactions to reduce potential dilution, with remaining proceeds for general corporate purposes including its oncology pipeline and debt management. The financing follows August volatility tied to positive Phase 3 data for the Merck-partnered personalized cancer vaccine intismeran, which showed a 49% reduction in recurrence or death risk in high-risk melanoma, and recent FDA approvals of updated Spikevax and mNEXSPIKE COVID-19 formulations for 2026–2027.